Two synthetic peptides, increasingly used together for their complementary GH-stimulating properties. CJC-1295 is a long-acting GHRH analog. Ipamorelin is a selective GHRP receptor agonist. The mechanism is robust. The longitudinal evidence is not.
No dedicated double-blind RCT has studied the combination in humans for periods exceeding 8 weeks.
Teichman 2006 — sustained dose-dependent increases in GH and IGF-1, no serious adverse events.
156 hypopituitary adults — sustained lean mass and lipid improvements, no cancer signal.
Feb 27, 2026 — HHS announced 14 of 19 restricted peptides moving toward legal compounding.
Two distinct receptor pathways. Two complementary half-lives. One tag team.
A raised GH baseline plus amplified pulsatile peaks — a secretion profile that more closely resembles youthful physiology than either agent alone.
Prolonged albumin-bound activation produces sustained tonic GH release. ~1,370 ng·h/mL stimulated AUC vs ~758 ng·h/mL unstimulated.
Selective ghrelin-receptor activation produces an acute physiological GH spike — without ACTH or cortisol co-stimulation.
Click a beat. Clinical observation and patient reports — uncontrolled but consistent across long-term users.
What we have, what we don't. Honest scoreboard before stepping into the ring.
Animal data and analogous GH-replacement studies — useful directional signal, imperfect translation.
Dose-dependent increase from 42 → 52 µm/day; body weight gain rose; total IGF-1 unchanged — suggests local rather than systemic anabolic action.
Counteracted methylprednisolone-induced loss of muscle strength and bone formation; protective in catabolic states.
Cortical and total BMC increases attributed to "increased growth of bones with increased dimensions" — structural, not just density.
In GHRH-knockout mice, CJC-1295 maintained normal body composition and growth — proof-of-concept for sustained GH restoration.
Different mechanism (exogenous GH vs secretagogue), but the downstream IGF-1 / tissue effects are analogous — the most clinically relevant longitudinal safety window currently available.
Click any card to see the detail and mitigation. The damage profile is mostly metabolic, mostly manageable, mostly under-studied.
Transient post-injection blood glucose elevation; chronic high-dose use without breaks elevates risk.
Elevated IGF-1 epidemiologically associated with colorectal, prostate, premenopausal breast cancer. No causal link to GH secretagogues established.
Long-term continuous stimulation theoretically risks GHS-R1a / GHRH receptor downregulation.
IGF-1 sodium-retaining effects; more common at higher CJC-1295 doses. One ibutamoren study reported a significant edema-related AE.
Local irritation, transient headaches early in treatment, GI effects more frequent at higher CJC doses (≥ 100 µg/kg).
Swedish cohort: childhood rhGH treatment associated with increased adult CVD events (HR 1.66–2.08). Different population, different mechanism.
Practitioner consensus where legally available. Frameworks, not trial-derived guidance.
The legal status has moved fast. Where we stand as of early 2026.
STATUS · 2026 · Not yet formally reinstated under finalized FDA policy. Legal compounding access depends on jurisdiction and evolving guidance.
The pharmacokinetic complementarity is well-characterized. Short-term GH/IGF-1 elevation is robustly demonstrated. The combination preserves physiological pulsatility and avoids cortisol co-stimulation — clear advantages over older GHRPs.
But controlled longitudinal data does not yet exist for the combination. Cancer incidence, cardiovascular outcomes, and sustained metabolic effects remain open questions. Proxy data is reassuring, not definitive.
Most prudent path: structured cycling, regular metabolic monitoring, medical supervision — especially with metabolic disease, family history of IGF-1-sensitive cancers, or cardiovascular risk.